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Objective
Familial Mediterranean fever (FMF) is an autosomal
recessive disease characterized by recurrent attacks of
fever and peritonitis, pleuritis, arthritis or an erysipelas-
like skin disorder. The disease may present at any age,
more than 80% of patients being symptomatic by the age
of 20 yr. Its main long-term complication is amyloid A
(AA) amyloidosis, a severe manifestation with poor prog-
nosis. Mutations in the MEFV gene, on chromosome
16th, is encoding a protein named as pyrin. We aim to
analyze clinical characteristics, subclinical inflammation,
and carried MEFV mutation in siblings with FMF.
Methods
We obtain FMF patients who were followed in Erciyes
University Faculty of Medicine, department of pediatric
rheumatology and their siblings. All children were evalu-
ated with a questionnaire containing 21 questions which
symptoms may be signs of FMF. All subjects were invsti-
gated for laboratory disease features, genetic analysis of
MEFV mutations.
Results
The study included 53 pediatric patients and their 76 sib-
ling total 129 children from 50 different families. In
patients, the most frequent mutations were homozygous
pM694V (60%), pM694V/pM680I (9.5%), pM694V/
pV726A (3.6%) and heterozygous pM694V mutation
(3.6%). Therefore, in siblings of the patients had mostly
homozygous pM694V (12%), pE148Q/P369S and hetero-
zygous pM694V mutation (35.5%) while 11 (14.5%) sibling
had no mutation in MEFV gene. We also completed a
questionnaire form included findings of FMF in all subject.
We obtained the typical history of FMF (the presence of
fever, recurrent typical attacks of FMF (including peritoni-
tis, pleuritis and arthritis); and transient inflammatory
response) in 9 of 76 siblings (12%) from the questionnaire.
In addition, the presence of rare but important manifesta-
tions such as erysipelas like erythema and leg pain of FMF
were determine in patients’ siblings. The exertional leg
pain had found in 21 siblings (28%) who carried at least
one mutation in the MEFV gene. Also we evaluated acute
phase reactants (ESR, CRP, SAA and S100A protein) in all
subjects. The siblings with homozygous mutation had ele-
vated levels of SAA and S100A protein than others.
Conclusion
Our findings showed that siblings with FMF had different
clinical findings each other. In these children should be
questioned in terms of FMF findings before screen muta-
tion in MEFV. Fever, serositis symptoms and musculos-
keletal symptoms in children, especially presence of
homozygous mutation, even if there has no typical
attacks, we believe that the colchicine treatment should
be considered.
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